Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 6/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | PKM | P14618 | 1/20 | 1.00 |
| ▸ | IDE | P14735 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | RIN1 | Q13671 | 1/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 1.00 |
| ▸ | HLCS | P50747 | 6/20 | 0.69 |
| ▸ | CA12 | O43570 | 7/20 | 0.56 |
| ▸ | CA1 | P00915 | 7/20 | 0.56 |
| ▸ | CA2 | P00918 | 7/20 | 0.56 |
| ▸ | CA9 | Q16790 | 7/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Biotin SCHEMBL826595 | 1.00 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL5376391 | 1.00 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL36572 | 1.00 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL9841217 | 1.00 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL410686 | 1.00 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL59420 | 1.00 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL23055065 | 1.00 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL21981206 | 1.00 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL20547409 | 1.00 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL22943835 | 1.00 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 212 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023154852-A1 | ANTIBODY BARCODED BEADS AND USES THEREOF | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2023-08-17 | — | — | WO | claimed |
| EP-3727351-A1 | ENGINEERED EXTRACELLULAR VESICLES FOR ENHANCED TISSUE DELIVERY | Cedars-Sinai Medical Center (US) | 2020-10-28 | — | — | EP | claimed |
| US-20260137621-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | DIASOME PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260124139-A1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | DIASOME PHARMACEUTICALS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20250288521-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | DIASOME PHARMACEUTICALS INC (US) | 2025-09-18 | — | — | US | disclosed |
| US-12391930-B2 | Polymerase compositions and kits, and methods of using and making the same | Life Technologies Corporation (US) | 2025-08-19 | — | — | US | disclosed |
| US-12338465-B2 | Polymerase compositions, methods of making and using same | Life Technologies Corporation (US) | 2025-06-24 | — | — | US | disclosed |
| US-20250163391-A1 | NUCLEOTIDE TRANSIENT BINDING FOR SEQUENCING METHODS | LIFE TECHNOLOGIES CORP (US) | 2025-05-22 | — | — | US | disclosed |
| US-12215383-B2 | Polymerase compositions and methods of making and using same | Life Technologies Corporation (US) | 2025-02-04 | — | — | US | disclosed |
| US-12163188-B2 | Polymerase compositions and methods | Life Technologies Corporation (US) | 2024-12-10 | — | — | US | disclosed |
| US-12152256-B2 | Nucleotide transient binding for sequencing methods | Life Technologies Corporation (US) | 2024-11-26 | — | — | US | disclosed |
| US-20080182971-A1 | PEPTIDE DERIVATIVES, AND THEIR USE FOR THE SYNTHESIS OF SILICON-BASED COMPOSITE MATERIALS | GENENCOR INTERNATIONAL, INC. (US) | 2008-07-31 | — | — | US | disclosed |
| US-7361731-B2 | Peptide derivatives, and their use for the synthesis of silicon-based composite materials | GENENCOR INTERNATIONAL, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| US-7279285-B2 | Method of reversibly disrupting a conjugate comprising a biotin compound and a biotin-binding compound | MAGNETIC BIOSOLUTIONS AB (SE) | 2007-10-09 | — | — | US | disclosed |
| US-20070218117-A1 | Supra molecular construct for delivery of interferon to a mammal | SDG, INC. | 2007-09-20 | — | — | US | disclosed |
| US-20070218117-A1 | Supra molecular construct for delivery of interferon to a mammal | SDG, INC. | 2007-09-20 | — | — | US | disclosed |
| WO-2005081622-A1 | METHODS AND COMPOSITIONS FOR THE DETECTION OF NITRIC OXIDE | PHARMACIA & UPJOHN COMPANY LLC (US) | 2005-09-09 | — | — | WO | disclosed |
| US-20040077024-A1 | Method of reversibly disrupting a conjugate comprising a biotin compound and a biotin compound | NORDIAG AB (SE) | 2004-04-22 | — | — | US | disclosed |
| US-20020155157-A1 | Compositions and methods for polynucleotide delivery | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION | 2002-10-24 | — | — | US | disclosed |
| US-6368813-B1 | FLAVORS OF AVADIN ANTIBIOTICS | THE TRUSTEES OF BOSTON UNIVERSITY | 2002-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070218117-A1 | Supra molecular construct for delivery of interferon to a mammal | HAVCR2, IFNAR1, MSR1 | TDP1 4728/4885MEN1 4097/4885ABL1 2979/4885 |
| US-20250288521-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | FABP2, FABP1, FABP6 | TDP1 4819/4885MEN1 966/4885ABL1 4375/4885 |
| US-20260137621-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | FABP2, FABP1, SGMS2 | TDP1 4755/4885MEN1 2415/4885ABL1 4626/4885 |
| US-20260124139-A1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | GPR119, INSR, FABP1 | TDP1 4833/4885MEN1 2073/4885ABL1 4576/4885 |
| US-12163188-B2 | Polymerase compositions and methods | POLN, POLI, POLRMT | TDP1 88/4885MEN1 4479/4885ABL1 1051/4885 |
| US-20040077024-A1 | Method of reversibly disrupting a conjugate comprising a biotin compound and a biotin compound | BTD, HLCS, MMAB | TDP1 3392/4885MEN1 2726/4885ABL1 2156/4885 |
| US-20020155157-A1 | Compositions and methods for polynucleotide delivery | POLN, NCLN, APOB | TDP1 905/4885MEN1 4306/4885ABL1 2230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.